With the launch of Project Sweetheart in the spring of 2014, Cure First has been actively pursuing the identification of less-toxic targeted therapies for ovarian and breast cancers. Currently, there are only two FDA-approved targeted therapies for ovarian cancer which patients can turn to after standard chemotherapy efforts fail: olaparib, a PARP inhibitor that is approved for use in BRCA-mutated cancers, and bevacizumab, an angiogenesis inhibitor that works by slowing the growth of blood vessels within the tumor. While these two drugs are both significantly less toxic than typical chemotherapies, patients often become resistant to them after 4 to 18 months, highlighting the dire need for therapies with long-term effectiveness.
Research Fellow Reid Shaw is focused on identifying targeted and less-toxic drugs that work synergistically with current treatments to prevent single-agent resistance and increase the progression-free survival. Reid’s interdisciplinary research strategy has identified two drug combinations that preferentially kill cancer cells while preserving the viability of normal cells. Project Sweetheart urgently needs funding in order for Reid to conduct an in vivo experiment using patient-derived ovarian cancer cells in avatar mice to make sure that the proposed combinations are safe and effective.
Our goal is to raise $50,000 so that we can fund this critical project and continue to expand treatment options for cancer patients. Your donation will directly support this vital trial and will help usher in the next generation of ovarian and breast cancer treatments.